Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2002

View Archived Issues

Angiogenix demonstrates angiogenic activity in preclinical trials

New data on the tolerability of gimatecan discussed at ESMO 2002

Chemotherapy-induced neuropathy reported to improve with levocarnitine acetyl hydrochloride

Marine-derived cytotoxic agents a highlight of the ESMO 2002 congress

Lack of efficacy of venlafaxine in fibromyalgia reported at ACR meeting

Vitaxin inhibits alphavbeta3 integrin expression in human synovial tissue engrafted in SCID mice

Pharmacopeia researchers design novel FSH modulators

New viral RNA polymerase inhibitors covered by BioCryst patent

Gruenenthal prepares and tests new antibacterial beta-lactam-siderophore conjugates

Novel triptolide prodrugs and their use in cancer and autoimmune diseases

Novartis claims malate salts of antifungal agent

Series of antiangiogenic and vascular-damaging agents under study at AstraZeneca

Guilford submits amendment to Gliadel Wafer sNDA

Semisynthetic ciclosporin derivatives for use in respiratory disorders prepared at Enanta

Ribapharm submits IND for Hepavir B

Enrollment begins in pivotal phase III trials of Atrisone for acne

Elan returns rights to HCV antisense drug to Isis

Isis and Elan extend collaboration in OraSense joint venture to end of year

Potential new antidementia drug from Fujisawa facilitates hippocampal neurotransmission

BSF-4007877 and BSF-4094664: neuroprotective 5-HT1A receptor agonists

Highly potent and selective 5-HT6 antagonist from Lilly is orally bioavailable and enters the brain

INO-1001 protects rats from ischemic stroke via inhibition of PARP

Erbitux clinical development program update

GPI-1485 enters new phase II trial in Parkinson's disease patients

December date set for advisory committee review of Bexxar

Fujisawa presents a potent new antioxidant, FR-210575, with potential in stroke

Myfortic receives first major approval in Switzerland

Orphan drug status granted for P-113D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.